Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Case report

Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease

Authors: Andrea Casadei Gardini, Michele Aquilina, Devil Oboldi, Alessandro Lucchesi, Silvia Carloni, Elena Tenti, Marco Angelo Burgio, Dino Amadori, Giovanni Luca Frassineti

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Systemic capillary leak syndrome is a rare disease with a high mortality rate. This syndrome is characterised by generalised edema, hypotension, hemoconcentration, and hypoproteinemia. The cause is the sudden onset of capillary hyperpermeability with extravasations of plasma from the intravascular to the extravascular compartment. We present the case of a patient who experienced two episodes of systemic capillary leak syndrome and pulmonary hypertension; the first after gemcitabine in an adjuvant setting and the second three years later after treatment with nab-paclitaxel for metastatic disease.

Case presentation

A 65-year-old patient underwent a pancreatectomy in January 2010 for ductal carcinoma (pT3 N0 M0, stage IIa), followed by adjuvant chemotherapy. Seven days after the last cycle, she developed dyspnea associated with orthopnea and cough. A transthoracic cardiac ecocolordoppler was performed, with evidence of pulmonary hypertension (58 mmHg). Blood tests showed an increase in creatinine, pro-BNP and D-Dimer. She began high-dose diuretic therapy combined with cortisone. After a month, the patient was eupneic and the anasarca had resolved. We decided gradually to reduce the steroid and diuretic therapy. After ten days of the reduction, the patient began to re-present the same symptoms after treatment with gemcitabine. Corticosteroid therapy was restored with rapid clinical benefit and decreased pro-BNP after a week of treatment. After two years, the disease returned. As a first line treatment, it was decided to use nab-paclitaxel 100 mg/m2 weekly. After two doses, followed by approximately 14 days of treatment, the patient developed acute respiratory distress syndrome. The clinical suspicion was a relapse of capillary leak syndrome and treatment with a high-dose diuretic (furosemide 250 mg daily) was started combined with cortisone (40 mg methylprednisolone). The patient showed a progressive clinical benefit.

Conclusions

In patients treated with gemcitabine and nab-paclitaxel who experience a sudden onset of diffuse edema with respiratory distress, capillary leak syndrome should be suspected. Immediate treatment with corticosteroids may be life-saving.
Appendix
Available only for authorised users
Literature
1.
go back to reference Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996, 73: 101-105. 10.1038/bjc.1996.18.CrossRefPubMedPubMedCentral Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996, 73: 101-105. 10.1038/bjc.1996.18.CrossRefPubMedPubMedCentral
2.
go back to reference Abbratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA: Efficacy and safety profile of gemcitabine in non-smallcell lung cancer: a phase II study. J Clin Oncol. 1994, 12: 1535-1540. Abbratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA: Efficacy and safety profile of gemcitabine in non-smallcell lung cancer: a phase II study. J Clin Oncol. 1994, 12: 1535-1540.
3.
go back to reference Coskun U, Günel N, Yildirim Y: Gemcitabine induced pulmonary injury. Case Rep Pract Rev. 2004, 5: 178-179. Coskun U, Günel N, Yildirim Y: Gemcitabine induced pulmonary injury. Case Rep Pract Rev. 2004, 5: 178-179.
4.
go back to reference Remuzzi G, Schieppati A, Ruggenenti P, Bertani T: Thrombotic thrombocytopenia purpura, hemolytic uremic syndrome, and acute cortical necrosis. Diseases of the Kidney. Edited by: Schrier RW, Gottschalk CW. 1993, Boston: Little, Brown and Company, 2063-2094. 5 Remuzzi G, Schieppati A, Ruggenenti P, Bertani T: Thrombotic thrombocytopenia purpura, hemolytic uremic syndrome, and acute cortical necrosis. Diseases of the Kidney. Edited by: Schrier RW, Gottschalk CW. 1993, Boston: Little, Brown and Company, 2063-2094. 5
5.
go back to reference Hosein PJ, Jr G, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM: A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. J Clin Oncol. 2013, 36: 151-156. 10.1097/COC.0b013e3182436e8c.CrossRef Hosein PJ, Jr G, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM: A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. J Clin Oncol. 2013, 36: 151-156. 10.1097/COC.0b013e3182436e8c.CrossRef
6.
go back to reference Aapro MS, Martin C, Hatty S: Gemcitabine - a safety review. Anticancer Drugs. 1998, 9: 191-201. 10.1097/00001813-199803000-00001.CrossRefPubMed Aapro MS, Martin C, Hatty S: Gemcitabine - a safety review. Anticancer Drugs. 1998, 9: 191-201. 10.1097/00001813-199803000-00001.CrossRefPubMed
7.
go back to reference Briasoulis E, Pavlidis N: Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist. 2001, 6: 153-161. 10.1634/theoncologist.6-2-153.CrossRefPubMed Briasoulis E, Pavlidis N: Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist. 2001, 6: 153-161. 10.1634/theoncologist.6-2-153.CrossRefPubMed
8.
go back to reference Pavlakis N, Bell DR, Millward MJ: Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997, 80: 286-291. 10.1002/(SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q.CrossRefPubMed Pavlakis N, Bell DR, Millward MJ: Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997, 80: 286-291. 10.1002/(SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q.CrossRefPubMed
9.
go back to reference Ciotti R, Belotti G, Facchi E, Cantù A, D’Amico A, Gatti C: Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine. Ann Oncol. 1999, 10: 997-10.1023/A:1008305716918.CrossRefPubMed Ciotti R, Belotti G, Facchi E, Cantù A, D’Amico A, Gatti C: Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine. Ann Oncol. 1999, 10: 997-10.1023/A:1008305716918.CrossRefPubMed
10.
go back to reference de Pas T, Curigliano G, Franceschelli L, Catania C, Spaggiari L, de Braud F: Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol. 2001, 12: 1651-1652. 10.1023/A:1013163831194.CrossRefPubMed de Pas T, Curigliano G, Franceschelli L, Catania C, Spaggiari L, de Braud F: Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol. 2001, 12: 1651-1652. 10.1023/A:1013163831194.CrossRefPubMed
11.
go back to reference Pulkkanen K, Kataja V, Johansson R: Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report. J Chemother. 2003, 15: 287-289.CrossRefPubMed Pulkkanen K, Kataja V, Johansson R: Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report. J Chemother. 2003, 15: 287-289.CrossRefPubMed
12.
go back to reference Nelson BK: Snake envenomation. Incidence, clinical presentation and management. Med Toxicol Adverse Drug Exp. 1989, 4: 17-31. 10.1007/BF03259900.PubMed Nelson BK: Snake envenomation. Incidence, clinical presentation and management. Med Toxicol Adverse Drug Exp. 1989, 4: 17-31. 10.1007/BF03259900.PubMed
13.
go back to reference Luce JM: Pathogenesis and management of septic shock. Chest. 1987, 91: 883-888. 10.1378/chest.91.6.883.CrossRefPubMed Luce JM: Pathogenesis and management of septic shock. Chest. 1987, 91: 883-888. 10.1378/chest.91.6.883.CrossRefPubMed
14.
go back to reference Parrillo JE, Parker MM, Natanson C, Parrillo JE, Parker MM: Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Intern Med. 1990, 113: 227-242. 10.7326/0003-4819-113-3-227.CrossRefPubMed Parrillo JE, Parker MM, Natanson C, Parrillo JE, Parker MM: Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Intern Med. 1990, 113: 227-242. 10.7326/0003-4819-113-3-227.CrossRefPubMed
15.
go back to reference Chang AE, Rosenberg SA: Overview of interleukin-2 as an immunotherapeutic agent. Semin Surg Oncol. 1989, 5: 385-390. 10.1002/ssu.2980050604.CrossRefPubMed Chang AE, Rosenberg SA: Overview of interleukin-2 as an immunotherapeutic agent. Semin Surg Oncol. 1989, 5: 385-390. 10.1002/ssu.2980050604.CrossRefPubMed
16.
go back to reference Semb KA, Aamdal S, Oian P: Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol. 1998, 16: 3426-3432.PubMed Semb KA, Aamdal S, Oian P: Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol. 1998, 16: 3426-3432.PubMed
Metadata
Title
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease
Authors
Andrea Casadei Gardini
Michele Aquilina
Devil Oboldi
Alessandro Lucchesi
Silvia Carloni
Elena Tenti
Marco Angelo Burgio
Dino Amadori
Giovanni Luca Frassineti
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-542

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine